・The Metsera buyout brings multiple obesity and cardiometabolic drug candidates into Pfizer’s pipeline, including a GLP-1 nearing Phase 3. ・Pfizer’s BioNTech position was reduced by 54.7%, leaving ...

Das US-Pharmaunternehmen Pfizer und sein Mainzer Partner Biontech haben eine klinische Studie gestartet, um ihren Corona-Impfstoff bei Schwangeren zu testen. Bei der Phase-2/3-Studie werden rund 4000 ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...

Add Yahoo as a preferred source to see more of our stories on Google. Pfizer Inc. signage is seen on July 22, 2020 in New York City. (Jeenah Moon via Getty Images) This story was originally published ...

Amid uncertainty over how the Trump administration would approach mRNA COVID-19 vaccines for the upcoming respiratory virus season, the FDA has approved updated shots from Pfizer and Moderna. But ...

Die Impfung mit dem Vakzin von Biontech/Pfizer senkt laut einer Studie das Risiko einer Infektion mit der Delta-Variante des Coronavirus bei Jugendlichen um 90 Prozent. Sie schütze zudem zu 93 Prozent ...

LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...

Pfizer has axed 11 programs including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage metabolic dysfunction-associated ...

A German court found Wednesday that American pharmaceutical giant Pfizer and German firm BioNTech violated a patent to make their COVID-19 vaccine. Siding with Moderna, an American pharmaceutical firm ...